Cidara Historical Financial Ratios

CDTX Stock

USD 19.59 0.90 4.82%

Cidara Therapeutics is presently reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 111 or Invested Capital of 0.0 will help investors to properly organize and evaluate Cidara Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

About Cidara Financial Ratios Analysis

Cidara TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cidara Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cidara financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cidara Therapeutics history.

Cidara Therapeutics Financial Ratios Chart

At this time, Cidara Therapeutics' Days Sales Outstanding is fairly stable compared to the past year. Capex To Depreciation is likely to rise to 4.49 in 2024, whereas Price To Sales Ratio is likely to drop 1.03 in 2024.

Price To Sales Ratio Days Sales Outstanding Stock Based Compensation To Revenue Ev To Sales Payables Turnover Capex Per Share

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Cidara Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cidara Therapeutics sales, a figure that is much harder to manipulate than other Cidara Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Stock Based Compensation To Revenue

A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from Cidara Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cidara Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.At this time, Cidara Therapeutics' Days Sales Outstanding is fairly stable compared to the past year. Capex To Depreciation is likely to rise to 4.49 in 2024, whereas Price To Sales Ratio is likely to drop 1.03 in 2024.

	2021	2022	2023	2024 (projected)
Graham Number	55.69	12.63	14.89	14.14
Receivables Turnover	9.26	11.02	3.93	3.74

Graham Number Receivables Turnover

Cidara Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		-0.13	-0.03	0.22	0.0	-0.51	0.09	-0.13	0.99	-0.48	-0.19	-0.48	-0.39	-0.16	0.29	-0.64	0.0	0.26	-0.22	-0.16	-0.35	-0.22	-0.23	-0.05	-0.17	-0.3
Ptb Ratio	-0.13		0.26	0.26	-0.41	0.15	-0.61	1.0	-0.12	0.11	-0.9	-0.09	-0.12	-0.2	0.26	0.11	0.23	0.33	0.32	-0.15	0.69	0.34	-0.38	-0.01	-0.9	0.71
Days Sales Outstanding	-0.03	0.26		-0.19	-0.32	0.33	-0.17	0.26	0.07	0.31	-0.26	0.4	0.23	-0.52	0.38	0.28	0.97	-0.22	0.35	0.12	0.35	0.35	-0.54	-0.09	-0.41	0.26
Book Value Per Share	0.22	0.26	-0.19		-0.31	-0.78	0.1	0.26	0.2	-0.81	-0.24	-0.06	-0.88	0.07	-0.11	-0.17	-0.17	0.98	0.12	-0.03	-0.17	0.15	0.1	-0.25	-0.26	0.47
Free Cash Flow Yield	0.0	-0.41	-0.32	-0.31		0.16	0.39	-0.41	-0.03	0.18	0.32	0.22	0.26	0.23	-0.04	0.07	-0.27	-0.24	-0.82	0.04	-0.37	-0.83	0.07	-0.22	0.4	-0.76
Operating Cash Flow Per Share	-0.51	0.15	0.33	-0.78	0.16		-0.47	0.15	-0.48	1.0	0.02	0.12	0.96	-0.11	0.23	0.38	0.29	-0.79	-0.04	0.07	0.66	-0.06	-0.26	0.24	-0.04	-0.04
Capex To Depreciation	0.09	-0.61	-0.17	0.1	0.39	-0.47		-0.61	0.1	-0.46	0.46	0.25	-0.34	0.41	-0.38	0.27	-0.06	0.11	-0.37	0.24	-0.89	-0.37	0.26	-0.19	0.54	-0.59
Pb Ratio	-0.13	1.0	0.26	0.26	-0.41	0.15	-0.61		-0.12	0.11	-0.9	-0.09	-0.12	-0.2	0.26	0.11	0.23	0.33	0.32	-0.15	0.69	0.34	-0.38	-0.01	-0.9	0.71
Ev To Sales	0.99	-0.12	0.07	0.2	-0.03	-0.48	0.1	-0.12		-0.44	-0.2	-0.44	-0.36	-0.14	0.33	-0.58	0.12	0.24	-0.19	-0.15	-0.32	-0.19	-0.3	-0.01	-0.19	-0.28
Free Cash Flow Per Share	-0.48	0.11	0.31	-0.81	0.18	1.0	-0.46	0.11	-0.44		0.04	0.1	0.97	-0.11	0.22	0.35	0.28	-0.82	-0.06	0.06	0.63	-0.08	-0.26	0.25	-0.02	-0.08
Roic	-0.19	-0.9	-0.26	-0.24	0.32	0.02	0.46	-0.9	-0.2	0.04		0.2	0.23	0.36	-0.31	0.06	-0.23	-0.33	-0.21	0.16	-0.47	-0.22	0.47	0.18	0.97	-0.51
Inventory Turnover	-0.48	-0.09	0.4	-0.06	0.22	0.12	0.25	-0.09	-0.44	0.1	0.2		0.08	-0.19	-0.44	0.36	0.36	-0.06	-0.01	-0.02	-0.08	-0.01	0.24	-0.1	0.16	-0.03
Net Income Per Share	-0.39	-0.12	0.23	-0.88	0.26	0.96	-0.34	-0.12	-0.36	0.97	0.23	0.08		-0.06	0.15	0.29	0.21	-0.9	-0.15	0.05	0.48	-0.17	-0.18	0.29	0.17	-0.26
Days Of Inventory On Hand	-0.16	-0.2	-0.52	0.07	0.23	-0.11	0.41	-0.2	-0.14	-0.11	0.36	-0.19	-0.06		-0.27	0.44	-0.34	0.08	-0.24	-0.05	-0.23	-0.23	0.12	0.4	0.43	-0.22
Payables Turnover	0.29	0.26	0.38	-0.11	-0.04	0.23	-0.38	0.26	0.33	0.22	-0.31	-0.44	0.15	-0.27		-0.14	0.37	-0.14	0.1	0.1	0.34	0.1	-0.73	-0.25	-0.38	0.12
Average Inventory	-0.64	0.11	0.28	-0.17	0.07	0.38	0.27	0.11	-0.58	0.35	0.06	0.36	0.29	0.44	-0.14		0.39	-0.2	0.09	0.12	0.2	0.09	-0.31	0.07	0.01	0.13
Capex To Revenue	0.0	0.23	0.97	-0.17	-0.27	0.29	-0.06	0.23	0.12	0.28	-0.23	0.36	0.21	-0.34	0.37	0.39		-0.2	0.3	0.11	0.29	0.3	-0.62	0.03	-0.37	0.2
Cash Per Share	0.26	0.33	-0.22	0.98	-0.24	-0.79	0.11	0.33	0.24	-0.82	-0.33	-0.06	-0.9	0.08	-0.14	-0.2	-0.2		0.03	-0.05	-0.2	0.07	0.13	-0.24	-0.32	0.41
Pocfratio	-0.22	0.32	0.35	0.12	-0.82	-0.04	-0.37	0.32	-0.19	-0.06	-0.21	-0.01	-0.15	-0.24	0.1	0.09	0.3	0.03		-0.15	0.38	1.0	-0.18	0.11	-0.28	0.77
Interest Coverage	-0.16	-0.15	0.12	-0.03	0.04	0.07	0.24	-0.15	-0.15	0.06	0.16	-0.02	0.05	-0.05	0.1	0.12	0.11	-0.05	-0.15		-0.19	-0.15	0.12	-0.23	0.16	-0.14
Capex To Operating Cash Flow	-0.35	0.69	0.35	-0.17	-0.37	0.66	-0.89	0.69	-0.32	0.63	-0.47	-0.08	0.48	-0.23	0.34	0.2	0.29	-0.2	0.38	-0.19		0.39	-0.44	0.23	-0.57	0.65
Pfcf Ratio	-0.22	0.34	0.35	0.15	-0.83	-0.06	-0.37	0.34	-0.19	-0.08	-0.22	-0.01	-0.17	-0.23	0.1	0.09	0.3	0.07	1.0	-0.15	0.39		-0.18	0.11	-0.3	0.79
Days Payables Outstanding	-0.23	-0.38	-0.54	0.1	0.07	-0.26	0.26	-0.38	-0.3	-0.26	0.47	0.24	-0.18	0.12	-0.73	-0.31	-0.62	0.13	-0.18	0.12	-0.44	-0.18		0.11	0.58	-0.22
Income Quality	-0.05	-0.01	-0.09	-0.25	-0.22	0.24	-0.19	-0.01	-0.01	0.25	0.18	-0.1	0.29	0.4	-0.25	0.07	0.03	-0.24	0.11	-0.23	0.23	0.11	0.11		0.19	0.01
Roe	-0.17	-0.9	-0.41	-0.26	0.4	-0.04	0.54	-0.9	-0.19	-0.02	0.97	0.16	0.17	0.43	-0.38	0.01	-0.37	-0.32	-0.28	0.16	-0.57	-0.3	0.58	0.19		-0.6
Ev To Operating Cash Flow	-0.3	0.71	0.26	0.47	-0.76	-0.04	-0.59	0.71	-0.28	-0.08	-0.51	-0.03	-0.26	-0.22	0.12	0.13	0.2	0.41	0.77	-0.14	0.65	0.79	-0.22	0.01	-0.6

Click cells to compare fundamentals

Cidara Therapeutics Account Relationship Matchups

Cidara Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	3.04	7.76	3.09	(18.2)	(8.46)	(8.88)
Book Value Per Share	25.28	5.16	8.23	(0.83)	(1.88)	(1.78)
Operating Cash Flow Per Share	(19.06)	(26.19)	(9.63)	(8.15)	(5.13)	(5.39)
Capex To Depreciation	0.0933	0.81	(0.0333)	0.0963	4.28	4.49
Pb Ratio	3.04	7.76	3.09	(18.2)	(8.46)	(8.88)
Free Cash Flow Per Share	(19.09)	(26.28)	(9.64)	(8.19)	(5.25)	(5.51)
Roic	(0.84)	(3.86)	(1.73)	10.33	3.61	3.79
Net Income Per Share	(26.78)	(34.83)	(16.75)	(8.53)	(5.25)	(5.51)
Payables Turnover	0.18	24.59	14.89	0.0988	0.4	0.38
Cash Per Share	40.27	17.28	23.76	9.37	8.18	7.78
Pocfratio	(4.03)	(1.53)	(2.64)	(1.86)	(3.09)	(3.25)
Interest Coverage	(188.8)	(274.23)	(199.32)	(155.59)	(140.03)	(147.03)
Capex To Operating Cash Flow	(0.001227)	(0.003418)	(0.001625)	(0.004144)	(0.0225)	(0.0236)
Pfcf Ratio	(4.02)	(1.52)	(2.63)	(1.85)	(3.03)	(3.18)
Days Payables Outstanding	14.84	24.51	2.5K	3.7K	903.99	1.3K
Income Quality	0.9	0.96	0.69	0.75	0.59	0.98
Roe	(1.06)	(6.75)	(2.04)	10.26	2.79	2.93
Ev To Operating Cash Flow	(2.33)	(1.01)	(0.37)	(0.75)	(1.72)	(1.8)
Pe Ratio	(2.87)	(1.15)	(1.52)	(1.77)	(3.03)	(3.18)
Return On Tangible Assets	(0.75)	(0.58)	(1.2)	(0.63)	(0.34)	(0.36)
Ev To Free Cash Flow	(2.32)	(1.01)	(0.37)	(0.75)	(1.68)	(1.76)
Earnings Yield	(0.97)	(0.35)	(0.87)	(0.66)	(0.56)	(0.33)
Current Ratio	2.18	1.48	2.11	1.5	0.9	0.86
Tangible Book Value Per Share	25.28	5.16	8.23	(0.83)	(1.88)	(1.78)
Graham Number	123.42	63.57	55.69	12.63	14.89	14.14
Shareholders Equity Per Share	25.28	5.16	8.23	(0.83)	(1.88)	(1.78)
Capex Per Share	0.0234	0.0895	0.0156	0.0338	0.12	0.11

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Cidara Historical Financial Ratios

About Cidara Financial Ratios Analysis

Cidara Therapeutics Financial Ratios Chart

Price To Sales Ratio

Stock Based Compensation To Revenue

Ev To Sales

Payables Turnover

Cidara Therapeutics fundamentals Correlations

Cidara Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cidara Therapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for Cidara Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Sales	+ 0.99	Price To Sales Ratio
Cash Per Share	+ 0.98	Book Value Per Share
Capex To Revenue	+ 0.97	Days Sales Outstanding

Cash Per Share	- 0.9	Net Income Per Share
Roe	- 0.9	Pb Ratio
Roic	- 0.9	Pb Ratio
Roe	- 0.9	Ptb Ratio
Roic	- 0.9	Ptb Ratio
Capex To Operating Cash Flow	- 0.89	Capex To Depreciation